Overview
Aliquot reports the narrow route-specific study and its limitations without converting it into a recommendation or broader route claim.
The reviewed study reports an average elimination half-life after intravenous administration in nine male healthy volunteers. Aliquot does not transfer that estimate to another route.
Human pharmacokinetic context
2.5 hours
Peer-reviewed human clinical study · intravenous administration
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- The reviewed study included nine male healthy volunteers.
- The published estimate is intravenous and is not evidence for subcutaneous pharmacokinetics.
- A small study average is not an individual prediction or a dosing interval.
- No U.S. approval conclusion is inferred from a database search.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers Limited human intravenous pharmacokinetic context and average elimination half-life.
- Drugs@FDA: FDA-approved drugs Regulatory database consulted; no compound-specific approval conclusion is asserted.
- Aliquot compound library methodology Editorial scope and route-matching rules.